Vyvgart Hytrulo — Medica

Generalized Myasthenia Gravis

Initial criteria

Patient is age ≥ 18 years
Patient has confirmed anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
Myasthenia Gravis Foundation of America classification is II to IV
Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 5
Patient meets ONE of the following: (a) Patient received or is currently receiving pyridostigmine; OR (b) Patient has had inadequate efficacy, a contraindication, or significant intolerance to pyridostigmine
Patient has evidence of unresolved symptoms of generalized myasthenia gravis (e.g., difficulty swallowing, difficulty breathing, or functional disability such as double vision, talking, or impairment of mobility)
Treatment cycles are no more frequent than every 50 days from the start of the previous treatment cycle
Medication is being prescribed by or in consultation with a neurologist

Patient is age ≥ 18 years
According to the prescriber, patient is continuing to derive benefit from Vyvgart Hytrulo (or Vyvgart Intravenous), such as reductions in exacerbations of myasthenia gravis or improvements in speech, swallowing, mobility, and respiratory function
Treatment cycles are no more frequent than every 50 days from the start of the previous treatment cycle
Medication is being prescribed by or in consultation with a neurologist

initial: 6 months; reauthorization: 1 year